WO2012021475A3 - ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF - Google Patents
ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF Download PDFInfo
- Publication number
- WO2012021475A3 WO2012021475A3 PCT/US2011/047002 US2011047002W WO2012021475A3 WO 2012021475 A3 WO2012021475 A3 WO 2012021475A3 US 2011047002 W US2011047002 W US 2011047002W WO 2012021475 A3 WO2012021475 A3 WO 2012021475A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amyloid beta
- beta peptide
- peptide antibodies
- n3pglu amyloid
- n3pglu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Anti-N3pGlu amyloid beta antibodies useful in the treatment of Alzheimer's Disease are provided.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37301610P | 2010-08-12 | 2010-08-12 | |
| US61/373,016 | 2010-08-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2012021475A2 WO2012021475A2 (en) | 2012-02-16 |
| WO2012021475A3 true WO2012021475A3 (en) | 2012-07-05 |
Family
ID=45568152
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2011/047002 Ceased WO2012021475A2 (en) | 2010-08-12 | 2011-08-09 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2012021475A2 (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20170004B1 (en) * | 2016-01-15 | 2022-09-15 | Lilly Co Eli | Anti-N3pGlu anti-amyloid beta-peptide antibody and its uses |
| AR107774A1 (en) * | 2016-03-16 | 2018-05-30 | Lilly Co Eli | COMBINATION THERAPY, METHOD FOR TREATMENT OF ALZHEIMER'S DISEASE |
| TWI735600B (en) | 2016-07-01 | 2021-08-11 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| US10988529B2 (en) | 2016-08-09 | 2021-04-27 | Eli Lilly And Company | Combination therapy |
| TW201827467A (en) | 2016-11-03 | 2018-08-01 | 比利時商健生藥品公司 | Antibodies to pyroglutamate amyloid-[beta] and uses thereof |
| JOP20190247A1 (en) * | 2017-04-20 | 2019-10-20 | Lilly Co Eli | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF |
| WO2020193644A1 (en) | 2019-03-26 | 2020-10-01 | Janssen Pharmaceutica Nv | ANTIBODIES TO PYROGLUTAMATE AMYLOID-ß AND USES THEREOF |
| JP2023535024A (en) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | anti-Abeta antibody |
| TWI843040B (en) * | 2021-01-11 | 2024-05-21 | 美商美國禮來大藥廠 | ANTI-N3pGlu AMYLOID BETA ANTIBODIES AND USES THEREOF |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| US20080050370A1 (en) * | 2006-03-17 | 2008-02-28 | Scott Glaser | Stabilized polypeptide compositions |
| US20100021478A1 (en) * | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
-
2011
- 2011-08-09 WO PCT/US2011/047002 patent/WO2012021475A2/en not_active Ceased
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122374B1 (en) * | 2002-04-09 | 2006-10-17 | Takaomi Saido | Amyloid beta-protein 3(pE)-42 antibodies and uses thereof |
| US20080050370A1 (en) * | 2006-03-17 | 2008-02-28 | Scott Glaser | Stabilized polypeptide compositions |
| US20100021478A1 (en) * | 2008-07-21 | 2010-01-28 | Probiodrug Ag | Diagnostic antibody assay |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012021475A2 (en) | 2012-02-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2012021475A3 (en) | ANTI-N3pGlu AMYLOID BETA PEPTIDE ANTIBODIES AND USES THEREOF | |
| BRPI1012853A2 (en) | protofibrillar beta-amyloid peptide-specific humanized antibodies | |
| UA107600C2 (en) | ANTIBODY AGAINST N3pGlu BETA-AMYLOID PAPIDE AND ITS APPLICATION | |
| IL254157B (en) | 14-3-3eta antibodies and uses thereof for the diagnosis and treatment of arthritis | |
| AU2018256498A1 (en) | Antibodies to amyloid beta | |
| CA2883095C (en) | Antibody and protein formulations | |
| AP2957A (en) | New antibodies specific of the Beta-amyloid peptides and their uses as diagnostic agents or drugs | |
| HUE038313T2 (en) | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies | |
| IL231201B (en) | Isolated antibody for therapy and diagnosis of tau-mediated pathology in alzheimer's disease | |
| IL220684A (en) | Formulation for anaplerotic therapy for alzheimer's disease and the aging brain | |
| LT2498620T (en) | Protein concentrates and isolates, and processes for the production thereof | |
| SG179095A1 (en) | Novel assay for the detection of amyloid beta peptides | |
| EP2651965A4 (en) | Cyclosporine analogue molecules modified at amino acid 1 and 3 | |
| IL232325A0 (en) | 18-methyl-6'7-methylene-3-oxo-17-pregn-4-ene-21,17b-carbolactones, pharmaceutical preparations comprising said compounds and use thereof in the treatment of endometriosis | |
| WO2013059530A3 (en) | Peptidomimetic macrocycles | |
| IL210364A (en) | Cyclic peptide analogue of the ß-amyloid peptide and uses thereof in the treatment or diagnosis of neurodegenerative diseases or conditions | |
| IL209336B (en) | Preparations for the treatment of overgrowth disorders and their uses | |
| EP2182978A4 (en) | Tissue kallikrein for the treatment of diseases associated with amyloid protein | |
| WO2011072257A3 (en) | Amyloid binding agents | |
| EP3086846A4 (en) | Diagnosing and treating alzheimer's disease | |
| EP3558340A4 (en) | Methods of using gm6 in diagnosing and treating alzheimer's disease | |
| BR112012006005A2 (en) | "peptides in the treatment of oxidative stress disorder" | |
| GB2458868B (en) | Fluphenazine based combination for use in the treatment of protein aggregation diseases | |
| ZA200908989B (en) | Enhancement of the efficacy of therapeutic proteins | |
| EP2565184B8 (en) | Therapeutic agent and preventative agent for alzheimer's disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11816897 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 11816897 Country of ref document: EP Kind code of ref document: A2 |